ANTIHEMOPHILIC FACTOR
Antihemophilic Factor Adverse Events Reported to the FDA Over Time
How are Antihemophilic Factor adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Antihemophilic Factor, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Antihemophilic Factor is flagged as the suspect drug causing the adverse event.
Most Common Antihemophilic Factor Adverse Events Reported to the FDA
What are the most common Antihemophilic Factor adverse events reported to the FDA?
| Adverse Event | 1329 (4.57%) |
| Factor Viii Inhibition | 975 (3.35%) |
| Hiv Infection | 513 (1.76%) |
| Pyrexia | 418 (1.44%) |
| Hepatitis C | 413 (1.42%) |
| Drug Exposure During Pregnancy | 411 (1.41%) |
| Drug Ineffective | 403 (1.38%) |
| Haemorrhage | 343 (1.18%) |
| Metal Poisoning | 256 (.88%) |
| Neurotoxicity | 241 (.83%) |
| Nausea | 232 (.8%) |
 Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Antihemophilic Factor, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Antihemophilic Factor is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Adverse Event Categories for Antihemophilic Factor
What are the most common Antihemophilic Factor adverse events reported to the FDA?
| Therapeutic And Nontherapeutic Effe... | 2028 (6.97%) |
| Infections - Pathogen Unspecified | 1516 (5.21%) |
| Viral Infectious | 1431 (4.92%) |
| Coagulopathies And Bleeding Diathes... | 1097 (3.77%) |
| Neurological | 989 (3.4%) |
| Epidermal And Dermal Conditions | 874 (3%) |
| Hematology Investigations | 836 (2.87%) |
| Procedural And Device Related Injur... | 810 (2.78%) |
| Chemical Injury And Poisoning | 741 (2.55%) |
| Bacterial Infectious | 730 (2.51%) |
| Respiratory | 693 (2.38%) |
| Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Antihemophilic Factor, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Antihemophilic Factor is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Common Uses of Antihemophilic Factor According to Those Reporting Adverse Events
Why are people taking Antihemophilic Factor, according to those reporting adverse events to the FDA?
| Haemophilia | 2208 |
| Factor Viii Deficiency | 1368 |
| Diabetes Mellitus | 1018 |
| Drug Use For Unknown Indication | 798 |
| Product Used For Unknown Indication | 554 |
| Idiopathic Thrombocytopenic Purpura | 441 |
| Show More |
Drug Labels
| Label | Labeler | Effective |
|---|---|---|
| Recombinate | Baxter Healthcare Corporation | 26-MAY-10 |
| Recombinate | Baxter Healthcare Corporation | 26-MAY-10 |
| Recombinate | Baxter Healthcare Corporation | 26-MAY-10 |
| Recombinate | Baxter Healthcare Corporation | 01-DEC-10 |
| Monoclate-p | CSL Behring LLC | 29-APR-11 |
| Alphanate | Grifols Biologicals Inc. | 30-JUN-11 |
| Hemofil M | Baxter Healthcare Corporation | 20-APR-12 |
| Xyntha | Wyeth BioPharma Division of Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer | 01-JUL-12 |
| Humate-p | CSL Behring GmbH | 11-JUL-12 |
| Advate | Baxter Healthcare Corporation | 12-JUL-12 |
| Xynthaplasma/albumin-free | Wyeth BioPharma Division of Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer | 31-JUL-12 |
| Koate -dvi | KEDRION BIOPHARMA, INC | 31-AUG-12 |
| Kogenate Fs | Bayer HealthCare LLC | 18-JAN-13 |
| Kogenate Fs | Bayer HealthCare LLC | 18-JAN-13 |
| Helixate Fs | CSL Behring LLC | 18-JAN-13 |
Antihemophilic Factor Case Reports
What Antihemophilic Factor safety concerns are being reported by doctors and researchers in the medical literature?
About Results
This report contains aggregated drug side effects and adverse events for Antihemophilic Factor. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Comments
Share your experience with Antihemophilic Factor.